Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

@inproceedings{Volkmann2016ChangesIP,
  title={Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease},
  author={Elizabeth R. Volkmann and Donald P Tashkin and Michael D Roth and Philip J. Clements and Dinesh Khanna and Daniel e. Furst and Maureen D. Mayes and Julio Charles and Chi-hong Tseng and Robert M. Elashoff and Shervin Assassi},
  booktitle={Arthritis research & therapy},
  year={2016}
}
BACKGROUND Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of interstitial lung disease (ILD) in an observational study of patients with systemic sclerosis (SSc). The purpose of the present study was to evaluate the relationship between baseline CXCL4 level and extent of ILD in the context of a randomized controlled trial and to determine whether changes in CXCL4 levels in response to immunosuppression are associated with future progression of SSc-ILD… CONTINUE READING